近距离放射治疗缓解食管癌吞咽困难:前瞻性研究的系统综述与荟萃分析
该系统综述纳入6项前瞻性研究共9个治疗组623例恶性吞咽困难患者,评估近距离放射治疗的疗效与安全性。治疗后1、3、6、9、12个月的无吞咽困难生存率分别为86.9%、67.2%、47.4%、37.6%和29.4%,严重不良事件率为22.6%,主要不良事件为狭窄和瘘管形成,结论认为近距离放射治疗高效且相对安全。
要点
- 近距离放射治疗后1个月无吞咽困难生存率为86.9%,3个月降至67.2%。
- 严重不良事件率22.6%,主要为狭窄(12.2%)和瘘管形成(8.3%)。
- 总辐射剂量和分次数量是唯一有正面影响的因素。
核心结论
- 近距离放射治疗是高度有效且相对安全的治疗选择,其使用不足不再合理。
- 需进一步研究确定能实现最高无吞咽困难生存率的最佳辐射剂量和分次数量。
研究设计与样本
- 系统综述与荟萃分析,纳入至少20例恶性吞咽困难患者的前瞻性研究,截至2016年4月发表。
- 共纳入6项研究,9个治疗组,623例患者;采用随机效应模型汇总无吞咽困难生存率和不良事件率。
主要发现
- 治疗后1个月无吞咽困难生存率为86.9%(95%CI: 76.0-93.3%)。
- 治疗后3个月无吞咽困难生存率为67.2%(95%CI: 56.1-76.7%)。
- 治疗后6个月无吞咽困难生存率为47.4%(95%CI: 38.5-56.5%)。
- 治疗后9个月无吞咽困难生存率为37.6%(95%CI: 30.0-45.9%)。
- 治疗后12个月无吞咽困难生存率为29.4%(95%CI: 21.6-38.7%)。
关键数值与推荐
- 严重不良事件率为22.6%(95%CI: 19.4-26.3)。
- 主要不良事件为近距离放射治疗相关狭窄(12.2%)和瘘管形成(8.3%)。
- 因食管穿孔导致死亡2例(0.3%)。
- 1、3、6个月评估的异质性较高,I2分别为86.3%、80.0%和57.8%。
- 荟萃回归分析显示总辐射剂量和分次数量是唯一有正面影响的因素。
临床怎么用
- 近距离放射治疗可作为食管癌所致吞咽困难的有效且相对安全的姑息治疗选择。
局限性
- 研究间在1、3、6个月评估时异质性高。
- 需进一步研究确定最佳辐射剂量和分次数量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of dysphagia owing to esophageal cancer is challenging. Brachytherapy has been proposed as an alternative option to stent placement. We performed a systematic review to examine its efficacy and safety in the resolution of dysphagia. METHODS: Prospective studies recruiting at least 20 patients with malignant dysphagia and published up to April 2016 were eligible. The dysphagia-free survival (DFS) and adverse event rates were pooled by means of a random effect model. RESULTS: Six studies for a total of 9 treatment arms (623 patients) were eligible for inclusion. After 1month since treatment, the DFS rate was 86.9% [95%CI: 76.0-93.3%]; after 3months, it was 67.2% [95%CI: 56.1-76.7%]; after 6months, it was 47.4% [95%CI: 38.5-56.5%]; after 9months, it was 37.6% [95%CI:30.0-45.9%]; and, finally, after 12months, it was 29.4% [95%CI: 21.6-38.7%]. The heterogeneity between studies was high at 1-, 3- and 6-month assessment; the values of I2 were 86.3%, 80.0% and 57.8%, respectively. The meta-regression analysis showed total radiation dose and number of fractions as the only positively influencing factors. Severe adverse event rate was 22.6% (95%CI 19.4-26.3). The main reported adverse events were brachytherapy-related stenosis (12.2%) and fistula development (8.3%). Two cases (0.3%) of deaths were reported due to esophageal perforation. CONCLUSION: Brachytherapy is a highly effective and relatively safe treatment option therefore its underuse is no longer justified. Further studies should investigate the optimal radiation dose and number of fractions able to achieve the highest DFS rates.
引用
- Fuccio L, Mandolesi D, Farioli A, et al. Brachytherapy for the palliation of dysphagia owing to esophageal cancer: A systematic review and meta-analysis of prospective studies. Radiother Oncol. 2017. PMID: 28104297. doi:10.1016/j.radonc.2016.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。